8-K: Adaptimmune to Delist from Nasdaq, Citing Cost Cuts

Adaptimmune Therapeutics plc announced its voluntary delisting from The Nasdaq Capital Market and subsequent deregistration to reduce costs and maximize value from remaining assets.

Summary

• Adaptimmune Therapeutics plc will voluntarily delist its American Depositary Shares (ADSs) from The Nasdaq Capital Market and deregister under Section 12(b) of the Exchange Act.
• The Board of Directors authorized the delisting on October 15, 2025, with notification sent to Nasdaq on October 16, 2025.
• Trading of ADSs on Nasdaq is expected to be suspended following the close of trading on or about October 27, 2025.
• The company intends to file a Form 25 with the SEC on or about October 28, 2025, to effect the delisting and deregistration.
• Deregistration is expected to become effective 90 days after the Form 25 filing.
• Following delisting, Adaptimmune plans to file a Form 15 to suspend SEC reporting obligations, certifying fewer than 300 shareholders of record.
• The company expects its ADSs to be quoted on the OTC Pink Limited Market, though continued trading is not guaranteed.
• The decision is driven by the desire to eliminate significant costs associated with SEC reporting, legal, audit, and Sarbanes-Oxley compliance, and to maximize value from remaining assets after the July 31, 2025, transaction with US WorldMeds.

Sentiment

Score: 2

Explanation: The delisting from Nasdaq, driven by non-compliance with listing rules and a stated need for cost reduction, is a significantly negative event for public shareholders. While management cites cost savings and value maximization, the loss of liquidity and transparency, coupled with the move to an illiquid OTC market, indicates a deteriorating public market position.

Positives

• The company aims to achieve significant cost reductions by eliminating expenses associated with SEC reporting, legal, audit, and Sarbanes-Oxley Act compliance.
• Management believes the delisting will facilitate efforts to maximize value from remaining assets, including programs targeting PRAME and CD70, following the transaction with US WorldMeds.

Negatives

• Voluntary delisting from Nasdaq will result in the loss of a major exchange listing, potentially reducing liquidity and investor access.
• The company previously received a notice on September 22, 2025, for failing to comply with Nasdaq's $1.00 minimum bid price rule, indicating underlying performance issues.
• Trading of ADSs post-delisting will be limited to privately negotiated sales and potentially the OTC Pink Limited Market, with no guarantee of a continuous trading market or broker participation.
• Suspension of SEC reporting obligations will reduce transparency and public disclosure for investors.

Risks

• Risks associated with, and the timing and effectiveness of, the company's voluntary delisting from Nasdaq.
• Uncertainties regarding eligibility for and timing of quotation on an OTC market.
• The trading of the company's ADSs following the voluntary delisting from Nasdaq may be illiquid or cease entirely.
• There is no guarantee that a broker will continue to make a market in the ADSs, or that trading will continue on an OTC market or otherwise.

Future Outlook

The company expects trading of its ADSs on Nasdaq to be suspended around October 27, 2025, followed by the filing of Form 25 for delisting and deregistration. Post-delisting, the company intends for its ADSs to be quoted on the OTC Pink Limited Market, though continued trading is not guaranteed. The company also plans to file a Form 15 to suspend SEC reporting obligations once it has fewer than 300 shareholders of record. Management aims to maximize value from remaining assets, including PRAME and CD70 programs, and is seeking strategic options for these assets.

Management Comments

• Adrian Rawcliffe, Chief Executive Officer: "As we noted previously, the transaction with USWM CT, LLC... represented the best path forward for Adaptimmune, our patients and other stakeholders."
• Adrian Rawcliffe, Chief Executive Officer: "Since closing the transaction on July 31, 2025, we have been restructuring to support the assets transferred to US WorldMeds, and have continued our efforts to maximize value from our remaining assets including programs targeting PRAME and CD70."
• Adrian Rawcliffe, Chief Executive Officer: "The delisting from Nasdaq and deregistration should facilitate cost reductions and further support our goal to maximize value going forward."

Industry Context

This delisting reflects a challenging environment for smaller biopharmaceutical companies, particularly those that have undergone significant asset divestitures. The decision to delist from a major exchange like Nasdaq, often driven by a combination of non-compliance with listing rules (like minimum bid price) and the high costs of public company compliance, is a trend seen when companies seek to conserve capital and focus on core operations or strategic alternatives outside the public market spotlight. The move to an OTC market typically results in reduced liquidity and investor visibility, which can be a significant hurdle for companies seeking to raise capital or maintain investor interest.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a significant reduction in liquidity for their ADSs, potential difficulty in trading, and reduced transparency due to the suspension of SEC reporting obligations. The value of their holdings may be negatively impacted.
• Management: Will benefit from reduced administrative burden and costs associated with public company compliance, allowing more focus on core business and asset maximization.
• Employees: Implied restructuring following the US WorldMeds transaction suggests potential impacts on workforce, though not explicitly detailed in this filing.
• Patients: The core assets (TECELRA, lete-cel, uza-cel) were transferred to US WorldMeds, so direct impact from this delisting on patient access to these therapies is indirect, but the company's continued efforts on PRAME and CD70 programs could still benefit future patients.

Next Steps

• Trading of ADSs on Nasdaq to be suspended on or about October 27, 2025.
• File Form 25 with the SEC on or about October 28, 2025, to effect voluntary delisting and deregistration.
• Deregistration of ADSs under Section 12(b) of the Exchange Act to become effective 90 days after Form 25 filing.
• File a Form 15 with the SEC to suspend filing obligations under the Exchange Act, certifying fewer than 300 shareholders of record.
• Seek quotation of ADSs on the OTC Pink Limited Market.
• Continue efforts to maximize value from remaining assets, including programs targeting PRAME and CD70.
• Seek strategic options for pre-clinical assets including PRAME directed T-cell therapy and CD-70 directed TRuC therapy.

Key Dates

Recommendation

The voluntary delisting from Nasdaq, coupled with prior non-compliance with listing rules, signals severe challenges for Adaptimmune. The move to an illiquid over-the-counter market and the suspension of SEC reporting will drastically reduce transparency and liquidity for investors. This significantly increases investment risk and makes it difficult for shareholders to exit positions, warranting a strong sell recommendation for any remaining public holdings.

Keywords

Adaptimmune Therapeutics, Nasdaq delisting, Deregistration, OTC Pink Market, Biopharmaceutical, Cell therapy, ADAP, SEC filing, Cost reduction, Shareholder value